Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
February 28 2023 - 7:30AM
Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of
therapies designed to activate the body's immune system to fight
cancer and infections, today announced plans to present updated
data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at
the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on
Women’s Cancer, to be held March 25-28 in Tampa, FL. Updated data
from an expansion cohort of the Phase 1 study of botensilimab in
combination with balstilimab (anti-PD-1) in patients with recurrent
platinum refractory/resistant ovarian cancer will be presented at
an oral plenary session on Monday, March 27th at 9:18am ET.
Presentation Details:
Abstract Title: Botensilimab, a
Novel Innate/Adaptive Immune Activator, plus Balstilimab
(Anti-PD-1) in Patients with Recurrent Platinum
Refractory/Resistant Ovarian Cancer (NCT03860272)Abstract
ID: 2Presenting Author: Bruno Bockorny,
MD, Harvard University, Beth Israel Deaconess Medical
CenterDetails: Scientific Plenary V: Progress:
Hitting Our Targets, 3/27/2023, 9:00am – 9:45am ET
The complete abstract will be available the morning of the
presentation at 9:00am ET. Data presented at the conference will be
available to view in the Publications section of the Agenus website
(https://agenusbio.com/publications) following the SGO
Conference.
About BotensilimabBotensilimab is a novel,
multifunctional CTLA-4 antibody that has been designed to extend
clinical benefits to “cold” tumors that do not respond to currently
approved immunotherapy-only regimens. In addition to binding to the
CTLA-4 receptor, its FC-enhanced structure induces memory immune
response, downregulates regulatory T cells, and delivers better
priming and activation of T cells, thereby amplifying immune
responses.
In a Phase 1b clinical study of more than 300 patients,
botensilimab has demonstrated clinical responses in nine solid
tumor cancers, either alone or in combination with Agenus’ PD-1
antibody, balstilimab. Agenus is conducting global, randomized
Phase 2 trials in microsatellite-stable colorectal cancer (MSS
CRC), pancreatic cancer, and melanoma as part of its ACTIVATE trial
program. A global Phase 3 trial in MSS CRC is planned to launch in
2023.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Forward Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to the use of botensilimab, for instance,
statements regarding therapeutic benefit and efficacy, mechanism of
action (including validation of mechanism of action), potency,
durability, and safety profile (including the absence of specific
toxicities) of the Company’s therapeutic candidates, both alone and
in combination with each other and/or other agents (e.g.,
botensilimab and/or balstilimab in combination); and any other
statements containing the words "may," "believes," "expects,"
"anticipates," "hopes," "intends," "plans," "forecasts,"
"estimates," "will," “establish,” “potential,” “superiority,” “best
in class,” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
ContactAgenus Inc.Zack ArmenHead of Investor
Relations917-362-1370zack.armen@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2024 to Jun 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2023 to Jun 2024